Wanbangde Pharmaceutical Group Co., Ltd.
Clinical trials sponsored by Wanbangde Pharmaceutical Group Co., Ltd., explained in plain language.
A Chinese pharmaceutical company involved in drug development and manufacturing.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Can a Three-Pronged therapy reboot the brain after injury? Results expected Dec 2026 (estimated)
- Can a natural compound from moss help the brain? a new trial investigates Results expected Dec 2026 (estimated)
-
Can a ginkgo pill soothe both chest pain and depression?
Disease control CompletedThis trial tests whether adding ginkgo biloba dropping pills to standard heart treatment can reduce chest pain episodes and improve quality of life in people with stable angina and depression. About 74 adults aged 18 to 75 with coronary heart disease and depressive symptoms will …
Phase 4 • Sponsor: Wanbangde Pharmaceutical Group Co., LTD • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Vitamin B12 injection showdown: are two versions identical?
Knowledge-focused CompletedThis study checks if a new version of methylconalamin (a type of vitamin B12) injection works the same as the current version. Twenty healthy adults will receive both injections at different times to compare how their bodies absorb the medicine. The goal is to see if the two form…
Phase 1 • Sponsor: Wanbangde Pharmaceutical Group Co., LTD • Aim: Knowledge-focused
Last updated Aug 26, 2026 00:00 UTC
-
Vitamin B12 injection showdown: are two versions the same?
Knowledge-focused CompletedThis early-stage trial checks whether a new methylconalamin injection works the same as an existing one in 14 healthy adults. Each person gets both versions at different times, and researchers measure drug levels in the blood. The goal is to see if they are bioequivalent, not to …
Phase 1 • Sponsor: Wanbangde Pharmaceutical Group Co., LTD • Aim: Knowledge-focused
Last updated Aug 26, 2026 00:00 UTC
-
Can a single injection of huperzine a unlock new treatments?
Knowledge-focused CompletedThis early-stage trial is testing how a single injection of huperzine A moves through the body and affects a key enzyme in red blood cells. Twelve healthy Chinese volunteers will receive the drug in four different ways to measure its concentration over time and its effect on acet…
Phase 1 • Sponsor: Wanbangde Pharmaceutical Group Co., LTD • Aim: Knowledge-focused
Last updated Aug 19, 2026 00:00 UTC